Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk

ANN ARBOR, Mich., – December 14, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk.  Silk from this production cycle was processed into finished reeled raw silk and happily received on-site by the Company’s Senior management this week. 

The delivery of this silk further reinforces the Company’s production model.  With this success, the Company is now accelerating its plans for the upcoming 2024 production season and beyond.

“I am very excited to have produced this small batch ahead of our upcoming field trials scheduled for this spring.  This early production bodes very well for the pending trials, and indicates, to me, that we are well on track to meet our 2024 production targets.  The purpose of the recently completed production batch was to test our production model.  The purpose of the upcoming field trials is to gain data from hybrids which we have developed over the last 12 months. Having those two pieces working together is key to commercial scale production.” said CEO and Founder Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories, Inc.

2723 South State Street Suite 150
Ann Arbor, Michigan 48104

Phone: (734) 619-8066

Corporate Website: www.KraigLabs.com

Email: corporate@KraigLabs.com